SeaStar Medical Targets $4.5B Adult Market With NEUTRALIZE-AKI Trial

SeaStar Medical is transitioning its commercialized pediatric kidney therapy toward the larger adult market, using upcoming clinical trial data and new federal reimbursement codes as growth catalysts. The company’s NEUTRALIZE-AKI trial for adult patients is currently over 65% enrolled, with completion expected between late 2026 and the first quarter of 2027.

"The first and only therapy that we know of to neutralize destructive hyperinflammation," said Eric Schlorff, Chief Executive of SeaStar Medical, during a recent presentation at the H.C. Wainwright Global Investment Conference.

Scaling from Pediatrics to Adult Care

The company’s pivot represents an expansion in addressable market size. While SeaStar Medical’s existing pediatric therapy serves a market estimated at $100 million, the adult acute kidney injury (AKI) sector is valued at approximately $4.5 billion annually. This shift toward the adult population aims to scale the company’s proprietary selective cytopheretic device (SCD) technology, which targets the hyper-inflammatory response associated with organ failure.

Regulatory and Reimbursement Milestones

The company is preparing for a financial milestone regarding its commercial reach. A Centers for Medicare & Medicaid Services (CMS) billing code for the inpatient use of the company's device is scheduled to take effect on October 1, 2026. This administrative development should provide the reimbursement framework to support the adoption of the therapy in adult intensive care settings.

Market Position and Financial Context

As of September 15, 2026, SeaStar Medical (NASDAQ: ICU) shares closed at $3.02. The company’s ability to navigate the transition from a niche pediatric application to the broader adult market remains a focus for analysts monitoring the small-cap biotech space. The success of the NEUTRALIZE-AKI trial is the hurdle for expanding the application of its SCD technology, which aims to provide an alternative to traditional dialysis-based interventions for patients suffering from severe AKI and systemic inflammation.